Transforming fermentation process development with a high-throughput automated bioreactor system

E. coli process development for recombinant protein production at Genentech has historically relied on 10 L traditional stainless steel bioreactors. This capacity was recently augmented with an ambr250 12-way bioreactor system, which has catalyzed a shift in our approach to early clinical process development. By dramatically increasing our throughput, the ambr250 has enabled more complete process parameter coverage resulting in an earlier understanding of process levers under shorter timelines.